This is a preview of subscription content, log in via an institution to check access.
Notes
2015 US dollars
cardiovascular death, nonfatal myocardial infarction or stroke
Reference
Kazi DS, et al. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. Journal of the American Medical Association 316: 743-753, No. 7, 16 Aug 2016. Available from: URL: http://dx.doi.org/10.1001/jama.2016.11004
Rights and permissions
About this article
Cite this article
PCSK9 inhibitors not cost effective for FH or ASCVD in US. PharmacoEcon Outcomes News 760, 27 (2016). https://doi.org/10.1007/s40274-016-3328-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3328-2